Canurta Therapeutics Partners with extractX to Integrate Proprietary Extraction Expertise into Enhanced Mobile Lab Platform

Toronto, ON — January 21, 2026 

Canurta Therapeutics (“Canurta”), a biotechnology company developing multi-target botanical therapeutics for complex inflammatory and neurological conditions, today announced a partnership with extractX Ltd. in connection with extractX’s enhanced Extraction Mobile Lab (EML 2.0) platform.

The EML 2.0 system is designed to provide Pharma-Grade mobile extraction capabilities for on-site botanical processing. Under the partnership, extractX is working with Canurta and leveraging Canurta’s patented extraction processes within its enhanced EML 2.0 labs. 

By integrating these proprietary methods, the EML 2.0 platform provides the ability to extract high value distillate and molecules, including rare polyphenols such as cannflavins, creating additional value for global processing partners without requiring additional costly processes. 

“This extractX – Canurta partnership allows our global processing partners to lead in their market in discovering and delivering new natural products. This capability is especially compelling for pharmaceutical and nutraceutical companies seeking differentiated, IP-protected ingredients derived from nature,”

stated Albert Iannantuono, CEO of extractX Ltd. 

Akeem Gardner, CEO of Canurta, added: 

“The vision for this initiative is inherently global. Health and wellness markets around the world are trending toward natural and plant-based solutions, and regulatory shifts such as cannabis rescheduling in the US are opening new avenues for polyphenol-rich extracts in medicine. extractX’s mobile labs are designed to meet international standards, enabling their partners to have unique advantages through the EML 2.0 abilities to produce Canurta products.” 

This partnership reflects a shared focus on advancing extraction science and enabling improved capture of differentiated botanical molecules within scalable, compliant mobile lab infrastructure. Further updates will be provided as implementation progresses. 

“We developed a whitepaper that dives into the science, infrastructure, and business model behind EML 2.0, revealing how partners can capture high-value polyphenols without heavy capital investment”

said Albert Iannantuono, CEO of extractX Ltd. Whitepaper can be found here.

About Canurta Therapeutics  

Canurta Therapeutics is a biotechnology company developing multi-target botanical therapeutics derived from rare hemp polyphenols. Through its Polykye™ AI platform, Canurta leverages advanced informatics to identify, optimize, and validate novel compounds for the treatment of neuroinflammation, antimicrobial resistance, and neurodegenerative diseases including ALS. The Company’s lead asset, CNR-401, is currently advancing through preclinical development with the goal of entering clinical trials. 

About extractX Ltd. 

extractX designs, builds, and supports industrial-scale, self-contained mobile extraction laboratories equipped with the most effective and reliable technology. Designed for 24/7 efficiency and unlimited scalability, our labs meet the demands of operations of any size. Built to GPP, GMP, and EU-GMP standards, extractX delivers purpose-built mobile extraction solutions—providing biomass cultivators and producers with on-site, on-demand service anywhere in the world. 

Forward-Looking Information   

This news release may contain forward-looking statements including, but not limited to, statements regarding the objectives, expected outcomes, commercial potential, and future project development opportunities contemplated by the MOU. Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks, uncertainties, and other factors that may cause actual results to differ materially. The MOU is non-binding and no project, investment, or commercial activity will proceed unless and until definitive agreements are executed between the Parties.    

For further information 

Akeem Gardner, CEO 

Canurta Therapeutics 

2425 Matheson Blvd E, Unit 807, Mississauga, ON L4W 5K4 

Akeem@canurta.com  

Albert Iannantuono, CEO 

extractX Ltd. 

129 Hagar Street, Unit 4 Suite 600, Welland, ON L3B 5V9 

905-327-5313